Ron Waksman1, Micaela Iantorno2. 1. Section of Interventional Cardiology, MedStar Washington Hospital Center, 110 Irving St., NW, Suite 4B-1, Washington, DC, 20010, USA. ron.waksman@medstar.net. 2. Section of Interventional Cardiology, MedStar Washington Hospital Center, 110 Irving St., NW, Suite 4B-1, Washington, DC, 20010, USA.
Abstract
PURPOSE OF REVIEW: This review will focus on our approach for the treatment of refractory in-stent restenosis. RECENT FINDINGS: The discovery of bare metal stents over three decades ago set a milestone in the evolution of percutaneous coronary intervention, which is currently the most widely performed procedure for the treatment of symptomatic coronary disease. However, the broad utilization of stents resulted in the new phenomenon of in-stent restenosis (ISR). Over the years, there has been an increase of the incidence of ISR despite continued improvement of drug-eluting stent (DES) technology. The mechanism of ISR is multifactorial, including biological, mechanical, patient, and operator-related factors. The most common factor is aggressive neointimal proliferation and neoatherosclerosis. ISR presentation is not benign, and treatment is challenging, especially in cases of DES-ISR. We review available therapy modalities for ISR, including medical therapy, scoring balloons, atheroablative therapies, repeat DES, vascular brachytherapy, drug-coated balloons, and coronary artery bypass grafting.
PURPOSE OF REVIEW: This review will focus on our approach for the treatment of refractory in-stent restenosis. RECENT FINDINGS: The discovery of bare metal stents over three decades ago set a milestone in the evolution of percutaneous coronary intervention, which is currently the most widely performed procedure for the treatment of symptomatic coronary disease. However, the broad utilization of stents resulted in the new phenomenon of in-stent restenosis (ISR). Over the years, there has been an increase of the incidence of ISR despite continued improvement of drug-eluting stent (DES) technology. The mechanism of ISR is multifactorial, including biological, mechanical, patient, and operator-related factors. The most common factor is aggressive neointimal proliferation and neoatherosclerosis. ISR presentation is not benign, and treatment is challenging, especially in cases of DES-ISR. We review available therapy modalities for ISR, including medical therapy, scoring balloons, atheroablative therapies, repeat DES, vascular brachytherapy, drug-coated balloons, and coronary artery bypass grafting.
Entities:
Keywords:
Balloon angioplasty; Bare metal stent; Drug-coated balloon; Drug-eluting stents; In-stent restenosis
Authors: F Alfonso; M J Pérez-Vizcayno; R Hernández; J Goicolea; A Fernández-Ortíz; J Escaned; C Bañuelos; C Fernández; C Macaya Journal: Am J Cardiol Date: 1999-04-15 Impact factor: 2.778
Authors: Donald E Cutlip; Amit G Chhabra; Donald S Baim; Manish S Chauhan; Sachin Marulkar; Joseph Massaro; Ameet Bakhai; David J Cohen; Richard E Kuntz; Kalon K L Ho Journal: Circulation Date: 2004-08-30 Impact factor: 29.690
Authors: George C M Siontis; Giulio G Stefanini; Dimitris Mavridis; Konstantinos C Siontis; Fernando Alfonso; María J Pérez-Vizcayno; Robert A Byrne; Adnan Kastrati; Bernhard Meier; Georgia Salanti; Peter Jüni; Stephan Windecker Journal: Lancet Date: 2015-08-15 Impact factor: 79.321
Authors: Bruno Scheller; Christoph Hehrlein; Wolfgang Bocksch; Wolfgang Rutsch; Dariush Haghi; Ulrich Dietz; Michael Böhm; Ulrich Speck Journal: N Engl J Med Date: 2006-11-13 Impact factor: 91.245
Authors: Raffaele Piccolo; Giulio G Stefanini; Anna Franzone; Ernest Spitzer; Stefan Blöchlinger; Dik Heg; Peter Jüni; Stephan Windecker Journal: Circ Cardiovasc Interv Date: 2015-04 Impact factor: 6.546
Authors: Noel M Caplice; T Jared Bunch; Paul G Stalboerger; Shaohua Wang; David Simper; Dylan V Miller; Stephen J Russell; Mark R Litzow; William D Edwards Journal: Proc Natl Acad Sci U S A Date: 2003-03-28 Impact factor: 11.205
Authors: George D Dangas; Bimmer E Claessen; Adriano Caixeta; Elias A Sanidas; Gary S Mintz; Roxana Mehran Journal: J Am Coll Cardiol Date: 2010-11-30 Impact factor: 24.094
Authors: David R Holmes; Paul Teirstein; Lowell Satler; Michael Sketch; James O'Malley; Jeffery J Popma; Richard E Kuntz; Peter J Fitzgerald; Hong Wang; Eileen Caramanica; Sidney A Cohen Journal: JAMA Date: 2006-03-12 Impact factor: 56.272
Authors: Christoph Stettler; Simon Wandel; Sabin Allemann; Adnan Kastrati; Marie Claude Morice; Albert Schömig; Matthias E Pfisterer; Gregg W Stone; Martin B Leon; José Suarez de Lezo; Jean-Jacques Goy; Seung-Jung Park; Manel Sabaté; Maarten J Suttorp; Henning Kelbaek; Christian Spaulding; Maurizio Menichelli; Paul Vermeersch; Maurits T Dirksen; Pavel Cervinka; Anna Sonia Petronio; Alain J Nordmann; Peter Diem; Bernhard Meier; Marcel Zwahlen; Stephan Reichenbach; Sven Trelle; Stephan Windecker; Peter Jüni Journal: Lancet Date: 2007-09-15 Impact factor: 79.321
Authors: Monika Colombo; Yong He; Anna Corti; Diego Gallo; Stefano Casarin; Jared M Rozowsky; Francesco Migliavacca; Scott Berceli; Claudio Chiastra Journal: Sci Rep Date: 2021-01-15 Impact factor: 4.379